Home / Market News / $XNCR
fiscal.ai Corporate Catalyst Impact 65/100 ● neutral

Wells Fargo and Barclays Adjust Price Targets for Xencor

Oct 27, 2026, 10:09 PM UTC · Primary ticker $XNCR

Wells Fargo and Barclays have both reiterated their Buy ratings on Xencor and increased their price targets. This positive adjustment by two major financial institutions is attributed to favorable clinical trial data for Xencor's drug candidates, including recent presentations at the ESMO Congress 2026.

Wells Fargo and Barclays have both raised their price targets for Xencor, with Wells Fargo moving from $30 to $44 and Barclays from $35 to $45, while maintaining their Buy ratings. This positive analyst action is a direct response to promising clinical trial data for Xencor's drug candidates, which was recently presented at the ESMO Congress 2026. This development is significant for Xencor as it signals increased confidence from institutional analysts in the company's pipeline and future prospects. For traders, this could lead to short-term positive momentum for XNCR stock, reflecting the upgraded outlook and potential for future drug approvals. The long-term implication is a stronger investment case for Xencor, though the key risk remains the successful progression and commercialization of its drug candidates.

$XNCR positive Increased price targets and reiterated Buy ratings
Source: fiscal.ai
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.